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MaBACKGROUND There is no effective medical treatment for heart failure with preserved ejection fraction (HFpEF).
Increases in pulmonary capillary wedge pressure (PCWP) develop in patients with HFpEF during exercise coupled with
impaired nitric oxide (NO) signaling. Nitrite can be reduced to bioactive NO in vivo, particularly under conditions of tissue
hypoxia, as with exercise.
OBJECTIVES This study sought to determine whether acute nitrite administration improves exercise hemodynamics
and cardiac reserve in HFpEF.
METHODS In a double-blind, randomized, placebo-controlled, parallel-group trial, subjects with HFpEF (N ¼ 28)
underwent invasive cardiac catheterization with simultaneous expired gas analysis at rest and during exercise, before
and 15 min after treatment with either sodium nitrite or matching placebo.
RESULTS Before the study drug infusion, HFpEF subjects displayed an increase in PCWP with exercise from
16  5 mm Hg to 30  7 mm Hg (p < 0.0001). After study drug infusion, the primary endpoint of exercise PCWP was
substantially improved by nitrite compared with placebo (adjusted mean: 19  5 mm Hg vs. 28  6 mm Hg; p ¼ 0.0003).
Nitrite-enhanced cardiac output reserve improved with exercise (þ0.5  0.7 l/min vs. 0.4  0.7 l/min; p ¼ 0.002) and
normalized the increase in cardiac output relative to oxygen consumption. Nitrite improved pulmonary artery pressure-
ﬂow relationships in HFpEF and increased left ventricular stroke work with exercise versus placebo, indicating an
improvement in ventricular performance with stress.
CONCLUSIONS Acute sodium nitrite infusion favorably attenuates hemodynamic derangements of cardiac failure that
develop during exercise in individuals with HFpEF. Prospective trials testing long-term nitrite therapy in this population
are warranted. (Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved
Ejection Fraction; NCT01932606) (J Am Coll Cardiol 2015;66:1672–82) © 2015 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
BP = blood pressure
CaO2  CvO2 = arteriovenous
oxygen content difference
cGMP = cyclic guanosine
monophosphate
CO = cardiac output
HFpEF = heart failure with
preserved ejection fraction
LV = left ventricular
NO = nitric oxide
PA = pulmonary artery
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1673designed to improve symptoms and outcome in
HFpEF.
Numerous lines of evidence indicate that abnor-
malities in nitric oxide (NO)–cyclic guanosine mono-
phosphate (cGMP) signaling play a central role in
causing these reserve limitations (11–13). Organic ni-
trates can improve NO-cGMP signaling but may be
limited by the development of tolerance or symptom-
atic hypotension (14,15). Indeed, 1 factor complicating
HFpEF treatment is that the hemodynamic perturba-
tions causing symptoms are often absent at rest but
observed only during physiological stresses, such as
exercise (2).SEE PAGE 1683 PCWP = pulmonary capillary
wedge pressure
PVR = pulmonary vascular
resistance
RAP = right atrial pressure
SV = stroke volume
SVR = systemic vascular
resistance
VO2 = oxygen consumption
VE/VCO2 = ventilatory
encyInorganic nitrite is now recognized as an alternative
in vivo source of NO-cGMP that is independent of the
traditional NO synthase pathway (16–19). Intriguingly,
the reduction of nitrite to bioactive NO may be
enhanced by tissue hypoxia and acidosis (19), which
develop during exercise. This suggests that nitrite
might more selectively target hemodynamic de-
rangements developing during stress in people with
HFpEF (2,10), with less risk of hypotension at rest (15).
The current study tests the hypothesis that, compared
with placebo, acute infusion of sodium nitrite would
improve exercise hemodynamics and enhance cardiac
reserve in patients with HFpEF.
METHODS
This double-blind, randomized, placebo-controlled,
parallel-group trial was designed to study the effects
of intravenous sodium nitrite on cardiovascular
hemodynamics at rest and during exercise in subjects
with HFpEF. Patients referred to the Mayo Clinic
cardiac catheterization laboratory for invasive
hemodynamic exercise stress testing were enrolled.
Written informed consent was provided by all subjects
before participation in study-related procedures. The
Mayo Clinic Institutional Review Board approved the
study.
STUDY POPULATION AND PROTOCOL. HFpEF was
deﬁned by clinical symptoms of chronic heart failure
(dyspnea, fatigue), normal ejection fraction ($50%),
and increased left heart ﬁlling pressures (pulmonary
capillary wedge pressure [PCWP]) at rest (>15 mm Hg)
and/or with exercise ($25 mm Hg) (1,2). Exclusion
criteria included signiﬁcant valvular heart disease
(>mild stenosis, >moderate regurgitation), cor pul-
monale, signiﬁcant pulmonary disease, congenital
heart disease, glucose 6-phosphate dehydrogenase
deﬁciency, left-to-right shunt, unstable coronary ar-
tery disease, myocardial infarction within 60 days,hypertrophic or inﬁltrative cardiomyopathy,
primary renal or hepatic disease, high-output
heart failure, or constrictive pericarditis.
Subjects receiving long-term treatment with
organic nitrates or phosphodiesterase 5 in-
hibitors also were excluded.
Subjects were studied on their long-term
medications in the post-absorptive state and su-
pine position. Cardiac catheterization was per-
formed with simultaneous expired gas analysis
at rest and during supine exercise at a 20-W
workload for 5 min, as previously described
(2,8). After the ﬁrst exercise phase (before any
drug administration) and after return to steady-
state baseline hemodynamic values, subjects
were randomized 1:1 to infusion of placebo
(normal saline solution) or sodium nitrite (50 mg/
kg/min) (Hope Pharmaceuticals, Scottsdale, Ari-
zona) for 5 min. The nitrite/placebo infusions
were identical in appearance andprepared by the
research pharmacy, ensuring double-blinding of
infusion content. After 10 min, hemodynamic
measurementswere repeated at rest, followed by
repeat supine exercise at a 20-W workload for 5
min, identical to the study’s ﬁrst phase. Arterial and
venous blood samples and hemodynamic and expired gas
data were acquired during each stage of the protocol.
Right heart catheterization was performed through
a 9-F sheath via the internal jugular vein. Transducers
were zeroed at mid-axilla. Right atrial pressure (RAP),
pulmonary artery (PA) pressure, and PCWP were
measured at end-expiration (mean of $3 beats) us-
ing 2-F, high-ﬁdelity micromanometer-tipped cathe-
ters (Millar Instruments, Houston, Texas) advanced
through the lumen of a 7-F, ﬂuid-ﬁlled catheter
(Arrow, Teleﬂex, Morrisville, North Carolina) (2,8).
Mean RAP and PCWP were taken at mid A wave.
PCWP position was veriﬁed by typical waveforms,
appearance on ﬂuoroscopy, and direct oximetry
(saturation $94%). Continuously recorded pressure
tracings were digitized (240 Hz) and analyzed ofﬂine.
Arterial blood pressure (BP) was measured contin-
uously through a 4- to 6-F radial arterial cannula.
Oxygen consumption (VO2) was measured from ex-
pired gas analysis (MedGraphics, St. Paul, Minnesota)
taken as the average from the 60 s preceding arterial
and mixed venous blood sampling (8). Ventilatory ef-
ﬁciency was assessed by the increase in minute venti-
lation relative to carbon dioxide production (VE/VCO2).
Arteriovenous O2 content difference (CaO2  CvO2) was
measured directly as the difference between systemic
arterial and PA O2 content. CO was determined by
the direct Fick method (VO2/[CaO2  CvO2]). Stroke
volume (SV) was determined from the quotient of CO
efﬁci
TABLE 1 Baseline Characteristics
Placebo (n ¼ 14) Nitrite (n ¼ 14) p Value
Age, yrs 70  8 69  6 0.7
Female 8 (57) 9 (64) 0.7
Caucasian 14 (100) 13 (93) 1.0
Body mass index, kg/m2 33.4  6.6 32.0  7.0 0.6
Comorbidities
Coronary disease 6 (43) 4 (29) 0.7
Hypertension 11 (79) 12 (86) 1.0
Diabetes 3 (21) 3 (21) 1.0
Medications
ACEI or ARB 6 (43) 11 (79) 0.12
Beta-blocker 4 (29) 7 (50) 0.4
Statin 7 (50) 8 (57) 1.0
Diuretic 7 (50) 6 (43) 1.0
Laboratory values
Hemoglobin, g/dl 13.3  1.7 13.0  1.1 0.6
Methemoglobin, % 0.5  4 0.7  0.4 0.2
Creatinine, mg/dl 0.9  0.3 1.0  0.3 0.5
NT-proBNP, pg/ml 585 (107–1,575) 249 (118–890) 0.4
Echocardiography
LVEDD, mm 46  5 48  4 0.6
LV mass index, g/m2 90  20 86  12 0.6
LV ejection fraction, % 62  6 65  6 0.2
Left atrial volume index, ml/m2 31 (28–43) 35 (31–46) 0.7
Mitral E velocity, cm/s 90  30 106  50 0.3
Mitral E/A ratio 1.1 (0.7–1.7) 1.0 (0.9–1.3) 0.8
Mitral e0 velocity, cm/s 7.3  1.5 7.7  1.9 0.6
E/e0 ratio 11 (9–18) 10 (9–28) 0.8
Values are mean  SD, n (%), or median (interquartile range).
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; LV ¼ left
ventricular; LVEDD¼ left ventricular end-diastolic diameter; NT-proBNP¼ N-terminal pro–B-type
natriuretic peptide.
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(mean PA  PCWP/CO), PA compliance (SV/PA pulse
pressure), and systemic vascular resistance (SVR)
(mean BP  RAP  80/CO) were calculated using stan-
dard formulas. LV systolic performance was assessed
by LV stroke work ([mean BP  PCWP]  SV  0.0136)
(2,8).
Central venous and arterial blood samples were
obtained during each stage to measure the methe-
moglobin level and blood gases. Plasma nitrite con-
centrations were assessed in the ﬁnal 6 subjects
enrolled in the trial using a liquid chromatography–
ﬂuorometric assay (BASi, West Lafayette, Indiana) as
previously described (20).
STUDY ENDPOINTS. The primary endpoint of the trial
was the PCWP during exercise. Secondary endpoints
included changes in resting PCWP as well as rest and
exercise changes in RAP, PA pressure, PVR, PA
compliance, systemic BP, heart rate, SV, stroke work,
CO, VO2, and Cao2  CvO2. Adequacy of CO reserve was
assessed by comparing the CO/VO2 slope before and
after study drug infusion, whereas PA pressure-ﬂowrelationships were assessed to integrate changes in
right heart loading with exercise. Methemoglobin
level (%) was assessed as a safety endpoint.
STATISTICAL ANALYSIS. Results are reported as
mean  SD, median (interquartile range) or n (%).
Between-group differences at individual time points
were tested using the Student t test, Wilcoxon rank
sum test, or Fisher exact test. Within-group differ-
ences are assessed by the paired Student t test. The
effect of nitrite on the primary endpoint of exercise
PCWP was assessed by analysis of covariance, using
the initial exercise PCWP measured before study drug
infusion as the covariate. Between-group differences
in rest or exercise hemodynamic responses were
compared by an unpaired Student t test after ac-
counting for respective pre-study drug values. Linear
regression was performed to compare hemodynamic
responses to exercise before and after study drug
infusion, with variables log-transformed as necessary
for analysis. All tests were 2-sided, with p < 0.05
considered signiﬁcant. Analyses were performed
using JMP version 10.0.0 (SAS Institute, Cary, North
Carolina).
RESULTS
A total of 28 subjects were enrolled in the trial be-
tween January and September 2014. Baseline char-
acteristics were not signiﬁcantly different between
treatment groups (Table 1). Subjects were older,
obese, and predominantly female, with a high prev-
alence of hypertension. On average, subjects dis-
played normal LV chamber size and mass, left atrial
enlargement, mild LV diastolic dysfunction, and
increased N-terminal pro–B-type natriuretic peptide
levels (Table 1).
At rest, subjects were hypertensive, with slightly
increased right and left heart ﬁlling pressures, mild
pulmonary hypertension, slightly increased PVR, and
normal CO (Table 2). With exercise, participants dis-
played signiﬁcant increases in heart rate, BP, CO, VO2,
and CaO2  CvO2. Mean RAP and PCWP increased
dramatically during exercise, with secondary increase
in PA pressures. Pulmonary vasodilation was impaired
during exercise, manifest by lack of a decrease in PVR
and acute decreases in PA compliance compared with
rest (Table 2). VE/VCO2 slope was increased (37  5),
consistent with marked ventilatory inefﬁciency dur-
ing exercise.
The increase in CO relative to metabolic demand
(DCO/DVO2 slope) in the HFpEF subjects was 4.7  2.7
ml/ml. Most participants (75%) displayed an
abnormal DCO/DVO2 slope (deﬁned as <6 ml/ml) (21),
indicating signiﬁcant limitation in CO reserve during
TABLE 2 Baseline and Exercise Hemodynamics Before Study Drug Infusion*
Rest 20-W Exercise
Placebo Nitrite Placebo Nitrite
Vital signs
Heart rate, beats/min 68  8 67  10 92  13† 91  21†
Systolic BP, mm Hg 155  15 152  23 179  22† 185  35†
Mean BP, mm Hg 98  7 96  13 113  13† 113  20†
Central pressures
RA, mm Hg 10  4 11  4 21  10† 20  7†
PA systolic, mm Hg 44  13 46  19 67  15† 67  26†
PA mean, mm Hg 28  7 28  12 47  12† 46  15†
PCWP, mm Hg 17  4 16  6 30  8† 30  7†
Vascular and ventricular function
PVR, mm Hg/l/min 2.3  1.7 2.5  1.5 2.5  1.8 2.3  1.6
PA compliance, ml/mm Hg 3.5  1.5 3.4  2.0 2.9  1.3‡ 2.8  1.3‡
SVR, DSC 1,370  360 1,480  610 1,000  370† 1,050  250†
LVSW, g/beat 89  24 82  24 98  23 92  27
Integrated function and metabolism
VO2, ml/min 233  50 214  41 731  168† 672  106†
CaO2  CvO2, ml/dl 4.4  1.0 4.4  0.9 9.4  1.2† 9.4  1.4†
CO, l/min 5.4  1.3 5.0  1.2 8.0  2.1† 7.3  1.7†
Stroke volume, ml 81  20 77  24 88  23 82  20
Values are mean  SD. *Columns show rest-exercise hemodynamics before study drug infusion in subjects
randomized to placebo or nitrite. All between-group comparisons at rest and with exercise are p ¼ not signiﬁcant.
†p < 0.0001 versus baseline, within-subject change. ‡p # 0.05 versus baseline, within-subject change.
BP ¼ blood pressure; CaO2  CvO2 ¼ arteriovenous O2 content difference; CO ¼ cardiac output; DSC ¼ dyne/
s∙cm5; LVSW ¼ left ventricular stroke work; PA ¼ pulmonary artery; PCWP ¼ pulmonary capillary wedge
pressure; PVR ¼ pulmonary vascular resistance; RA ¼ right atrial; SVR ¼ systemic vascular resistance;
VO2 ¼ oxygen consumption; W ¼ watt.
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relative to CO (DPA/DCO slope) was 9.4 (interquartile
range: 5.3 to 14.3) mm Hg/l/min. The vast majority of
subjects (93%) displayed abnormal PA pressure-ﬂow
relationships with exercise (deﬁned as >3.0 mm Hg/
l/min) (22). There were no between-group differences
in any of the indexes of resting or exercise hemody-
namics, expired gas data, or ventricular function.
NITRITE EFFECTS. Hypotension or other adverse
events after study drug infusion did not develop in
any subjects. Nitrite modestly increased methemo-
globin levels compared with placebo (þ0.5  0.3%
vs. þ0.1  0.4%; p ¼ 0.002), but no clinically mean-
ingful methemoglobinemia developed in any subject
(>5%). The highest methemoglobin level observed
(2.4%) was in a subject randomized to nitrite with an
increased resting level (1.6%).
Compared with placebo, nitrite infusion modestly
reduced RAP, PCWP, and PA pressures at rest
(Table 3). There was no statistically signiﬁcant effect
of nitrite on resting heart rate, BP, PVR, SVR, PA
compliance, LV stroke work, VO2, CO, CaO2  CvO2, or
SV compared with placebo.
The primary endpoint of exercise PCWP was
signiﬁcantly improved with nitrite compared with
placebo (adjusted mean: 19  5 mm Hg vs. 28 
6 mm Hg; p ¼ 0.0003) (Table 4, Figure 1A). The
magnitude of decrease in exercise PCWP was similar
across all PCWP values achieved during the initial
exercise phase (Figure 1B), and the decrease in exer-
cise PCWP remained signiﬁcant after adjusting for
renin-angiotensin inhibitor and beta-blocker use
(both p # 0.001). Nitrites reduced exercise PCWP
more than 2-fold greater than the reduction in resting
PCWP (mean difference: 8.1  1.4 mm Hg; p < 0.0001),
indicating a greater effect of nitrite on stress PCWP
compared with resting PCWP.
Nitrite had no effect on exercise heart rate or sys-
tolic BP, but it tended to reduce mean BP during
exercise more than placebo (p ¼ 0.05) (Table 4). Ni-
trite decreased exercise RAP and PA pressure
compared with placebo (Figure 2, Table 4). The
nitrite-mediated decrease in exercise PA pressure
was exclusively due to lowering of the PCWP, as
there was no effect on exercise PVR or PA compli-
ance. Nitrite tended to reduce VE/VCO2 slope
compared with placebo (0  2 vs. þ1  3; p ¼ 0.2).
Exercise SVR was reduced with nitrite, consistent
with systemic arterial vasodilation (Figure 2B). Nitrite
lowered the slope of the PA pressure-ﬂow relation-
ship compared with placebo (change in log DPA/DCO:
1.2  1.1 vs. 0.0  0.6; p ¼ 0.002; ANCOVA p ¼ 0.004)
(Figures 2C and 2D).By design, the external workload performed during
exercise was equivalent before and after study drug
infusion (20 W), but despite this, nitrite slightly
increased the VO2 achieved at 20 W compared with
placebo (Table 4); this VO2 increase was coupled to
greater enhancement in exercise CO (Figure 3A), with
no change in CaO2  CvO2 compared with to placebo
(Table 4). Nitrite infusion increased the DCO/DVO2
slope compared with placebo (þ2.1  2.2 ml/ml vs.
þ0.3  1.7 ml/ml; p ¼ 0.025) to a mean value that falls
within the normal range for humans without heart
failure (dotted line, Figure 3B), indicating an improve-
ment in CO reserve relative to metabolic demand.
The increase in exercise CO with nitrite was caused
exclusively by greater enhancement in SV (Figure 3C),
as there was no effect on exercise heart rate (Table 4).
Although the enhanced SV reserve with nitrite
might have been related in part to systemic vasodi-
lation (lower SVR), importantly, there was also a
greater increase in LV stroke work with nitrite
(Figure 3D), indicating an acute increase in LV systolic
performance, independent of changes in cardiac
loading (23).
PLASMA NITRITE LEVELS. Venous plasma nitrite
levels were obtained in 4 subjects randomized to
TABLE 3 Effects of Nitrite on Resting Hemodynamics*
Placebo (n ¼ 14) Nitrite (n ¼ 14) p Value
Vital signs
Heart rate, beats/min 3  5 0  5 0.15
Systolic BP, mm Hg 2  10 7  8 0.11
Mean BP, mm Hg 1  6 3  4 0.2
Central pressures
RA, mm Hg þ0  1 2  2 0.0003
PA systolic, mm Hg 3  4 8  5 0.01
PA mean, mm Hg 1  3 6  3 0.002
PCWP, mm Hg 0  1 3  3 <0.0001
Vascular and ventricular function
PVR, mm Hg/l/min 0.4  0.6 0.3  0.4 0.7
PA compliance, ml/mm Hg 0.2  0.6 0.8  1.3 0.1
SVR, DSC 20  160 140  350 0.3
LVSW, g/beat 0  9 6  18 0.3
Integrated function and metabolism
VO2, ml/min 6  15 2  38 0.8
CaO2  CvO2, ml/dl 0  0.4 0.4  0.5 0.1
CO, l/min 0.2  0.5 0.4  0.8 0.4
Stroke volume, ml 1  9 5  16 0.4
Values are mean  SD. *Table shows baseline-corrected values (resting values after receiving
study drug minus resting values before study drug).
Abbreviations as in Table 2.
TABLE 4
Vital signs
Heart ra
Systolic
Diastoli
Central pr
RA, mm
PA systo
PA mea
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Vascular a
PVR, mm
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SVR, DS
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Integrated
VO2, ml
CaO2 – C
CO, l/m
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1676nitrite and 2 randomized to placebo. Levels were
undetectable at baseline and with exercise before
study drug infusion in all subjects. Nitrite levels
remained undetectable after study drug infusion
in subjects receiving placebo, but increased toEffects of Nitrite on Exercise Hemodynamics*
Placebo (n ¼ 14) Nitrite (n ¼ 14) p Value
te, beats/min 0  3 1  6 0.3
BP, mm Hg 2  10 5  13 0.2
c BP, mm Hg 0  2 5  8 0.05
essures
Hg 1  2 5  2 0.0002
lic, mm Hg 4  8 11  6 0.01
n, mm Hg 2  5 10  4 0.0002
m Hg 2  5 11  5 0.0002
nd ventricular function
Hg/l/min 0.2  0.4 0  0.4 0.3
pliance, ml/mm Hg 0.5  0.9 0.8  0.9 0.3
C 70  100 70  140 0.007
/beat 2  8 15  12 0.0003
function and metabolism
/min 30  67 70  138 0.02
vO2, ml/dl 0  0.6 0.2  0.4 0.6
in 0.4  0.7 0.5  0.7 0.002
olume, ml 5  6 7  8 0.0002
mean  SD. *Table shows exercise baseline-corrected values (exercise values after
udy drug minus exercise values prior to study drug).
ions as in Table 2.8.39  1.88 mM at rest in subjects receiving active drug
(p ¼ 0.004 vs. baseline). After the 5-min exercise
period, levels decreased to 3.36  0.42 mM in the
active therapy group (p < 0.01 compared with pre-
exercise values). The calculated half-life from these
data was 3.9  0.6 min, which is 10-fold faster than
the previously reported kinetics for sodium nitrite in
humans at rest (30 to 40 min) (20), indicating active
consumption during exercise.
DISCUSSION
This double-blind, randomized, placebo-controlled
trial tested the effects of acute infusion of inorganic
sodium nitrite on cardiovascular hemodynamics and
ventricular function at rest and during low-level ex-
ercise in subjects with HFpEF. The rationale for this
design was based on the fact that hemodynamic de-
rangements in patients with HFpEF often develop
only during exercise, when a reduction of nitrite to
NO is believed to be enhanced because of tissue
hypoxia. The primary endpoint of exercise PCWP was
signiﬁcantly improved by nitrite, resulting in a 37%
reduction in left heart ﬁlling pressures with exercise
(Central Illustration). Beneﬁcial reductions in PCWP
were coupled to improvements in exercise CO
reserve, reductions in PA pressures and PA pressure-
ﬂow relationships, and enhanced systemic vasodi-
lator reserve.
Importantly, nitrite therapy was associated with
beneﬁcial myocardial effects in addition to vascular
effects, evidenced by a greater increase in LV stroke
work with exercise, an integrated index of LV dia-
stolic and systolic performance. Beneﬁcial effects on
hemodynamics and ventricular function were of
greater magnitude during exercise compared with
rest, and, among participants with nitrite levels
assessed, there was greater than expected decay
in nitrite levels during exercise, consistent with
active nitrite consumption. The beneﬁcial effects of
acute nitrite infusion on multiple hemodynamic de-
rangements developing during exercise in HFpEF
provides compelling rationale to pursue longer term
clinical trials of inorganic nitrites in patients with
HFpEF, a population for whom there is currently no
effective treatment.
PATHOPHYSIOLOGY OF HFpEF AND RATIONALE
FOR NO-ENHANCING THERAPIES. The pathophysi-
ology of HFpEF is complex, related to abnormalities
in LV diastolic function and diastolic reserve as
well as to limitations in systolic reserve, abnormal
peripheral and pulmonary vasodilation, endothe-
lial dysfunction, chronotropic incompetence, right
ventricular dysfunction, and, as recently shown,
FIGURE 1 Effects of Nitrite on Exercise Pulmonary Wedge Pressure
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(A) Compared with placebo (blue), nitrite infusion (red) signiﬁcantly lowered the exercise pulmonary capillary wedge pressure (PCWPEX)
relative to the pre-study drug exercise phase. Error bars ¼ SEM. (B) The magnitude of reduction in PCWPEX was similar across pre-study drug
PCWPEX levels. ANCOVA ¼ analysis of covariance; PCWP ¼ pulmonary capillary wedge pressure.
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1677limitations in the periphery (1–8,10,11,24–26). The
subjects enrolled in the current study displayed many
of these hemodynamic abnormalities, with a slight
increase in resting RAP, PA pressure, and PCWP and
dramatic increases during exercise that were coupled
to limitations in CO reserve and abnormal pulmonary
vascular function. These hemodynamic abnormalities
importantly contribute to central congestion and
inadequate tissue perfusion during stress and, thus,
represent viable targets for therapeutic intervention.
Previous trials testing inhibitors of the renin-
angiotensin-aldosterone system failed to show
beneﬁt in HFpEF, and there is currently no proven
treatment (1). Numerous lines of evidence point to
limitations in NO-cGMP as playing a key role in
determining the functional and hemodynamic ab-
normalities developing in HFpEF (11–13). Sildenaﬁl,
an inhibitor of phosphodiesterase-5 (which catabo-
lizes cGMP), did not enhance exercise capacity or
clinical status in a recent multicenter trial (27).
However, elegant work from van Heerebeek et al. (12)
showed that cGMP limitation in HFpEF is not related
to excessive breakdown but rather inadequate pro-
duction, suggesting that NO-cGMP–providing thera-
pies may be the more effective approach. A major
barrier in managing many patients with HFpEF is
related to the fact that the increase in cardiac ﬁlling
pressures and PA pressure is conﬁned to exercise,
whereas hemodynamics at rest may be more normal
(1–8). Thus, an agent that enhances NO-cGMP
signaling preferentially during exercise would be
expected to provide more targeted hemodynamic
improvements precisely at the time of greatest need.THE NITRATE-NITRITE-NO PATHWAY IN HEART
FAILURE. Inorganic nitrite and nitrate were pre-
viously considered to be inert byproducts of NO
metabolism, but recent work has shown these serve
as an important in vivo reservoir of NO (16–19).
Dietary nitrate is absorbed, secreted in saliva, and
then converted by oral bacteria to nitrite, which is
absorbed and then reduced by a number of enzymes,
including deoxygenated hemoglobin or myoglobin, to
NO (19,28,29). This reaction is believed to be
enhanced in the setting of hypoxia and acidosis,
which develop in the tissues and venous circulation
during exercise, potentially allowing for hypoxic
vasodilation that complements the alternative
oxygen-dependent NO synthase pathway (16,18,19).
In contrast to the organic nitrates that require alde-
hyde dehydrogenase and other enzymes for activa-
tion (14), there is no tolerance with nitrate-nitrite (17).
The greater reduction in SVR with exercise in the
current study is consistent with previously described
vasodilatory effects in humans, and the fact that
SVR reduction was only observed during exercise is
consistent with the hypoxia potentiation of nitrite
effect (16–18).
Recent studies have begun to explore the potential
role for the nitrate-nitrite-NO pathway in the treat-
ment of heart failure. Zamani et al. (30) performed a
noninvasive double-blind, crossover study in 17
subjects with HFpEF comparing nitrate-rich beetroot
juice with nitrate-depleted beetroot juice. The authors
observed signiﬁcant improvements in peak VO2, peak
exercise workload, exercise CO (assessed by echo-
cardiography), and exercise vasodilation (reduction
FIGURE 2 Effects of Nitrite on Pulmonary and Systemic Vascular Load
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Compared with placebo (blue), nitrite (red) signiﬁcantly reduced exercise pulmonary artery pressure (PA meanEX) (A) and exercise
systemic vascular resistance (SVREX). Error bars ¼ SEM (B). Placebo infusion did not alter the pulmonary artery pressure (PAP)-ﬂow (CO)
relationship with exercise (C), whereas nitrite infusion shifted the PAP-ﬂow relationship down, with a reduction in slope (D). Data points in
C and D are mean pressure and CO coordinates for the groups; p values reﬂect a paired Student t test comparing log PAP-ﬂow slopes before
versus after study drug infusion in the placebo and nitrite groups. CO ¼ cardiac output.
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1678in SVR) (30). The improvement in CO reserve observed
with nitrate therapy was due to a greater increase in
heart rate, with no signiﬁcant effect on SV.
The current invasive hemodynamic data extend
the noninvasive ﬁndings of Zamani et al. (30),
showing greater increases in CO and improved sys-
temic vasodilation with nitrite in HFpEF subjects,
assessed using gold-standard techniques. The in-
crease in CO noted in the current study greatly
exceeded the small increase in VO2, indicating an
acute increase in the ability of the heart to provide
blood ﬂow relative to metabolic needs (CO/VO2 slope),
which has been shown to be impaired on average in
HFpEF (10). In contrast to Zamani et al. (30), the
enhanced CO reserve observed in the current study
was related to a greater increase in SV with exercise,
with no effect on rest or exercise heart rate.
Although the greater increase in SV in the current
study was likely mediated in part by improved after-
load reduction, we also observed beneﬁcial effects ofnitrite on ventricular performance, assessed by the
greater increase in LV stroke work with exercise.
Stroke work is independent of afterload, but varies
directly with preload (end-diastolic volume) (23).
Therefore, we cannot determine whether the
beneﬁcial effect of nitrite on LV performance in the
current study was mediated by improvements in dia-
stolic reserve (greater increase in end-diastolic volume
despite lower ﬁlling pressures), systolic reserve
(increased contractility), or both. However, given the
fact that both diastolic and systolic reserves are
known to contribute to the pathophysiology of HFpEF,
the observation of a direct myocardial beneﬁt from
nitrite is an important observation.
The main novel ﬁnding and primary endpoint of the
trial was the greater reduction in PCWP during exer-
cise, a key force mediating symptoms of exertional
dyspnea in people with HFpEF. The magnitude of
decrease in exercise PCWP with nitrite was much
greater than the resting PCWP, consistent with greater
FIGURE 3 Effects of Nitrite on CO Reserve and Ventricular Performance
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Compared with placebo (blue), nitrite (red) infusion caused a greater increase in CO with exercise (A) and increased the slope of the increase in
CO relative to metabolic demand (VO2) toward normal values (6 ml/ml; dotted line) (B). Enhanced CO reserve with nitrite was due to greater
increases in SV with exercise (C) along with greater increases in left ventricular stroke work with exercise (D). Error bars ¼ SEM; CO ¼ cardiac
output; LVSW ¼ left ventricular stroke work; SV ¼ stroke volume; VO2 ¼ oxygen consumption.
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1679effectiveness of nitrite during exercise, as noted
earlier. This represents an important advantage of
inorganic nitrite for HFpEF patients, especially those
with early-stage disease in which PCWP is normal at
rest and increased only during exercise. The decrease
in exercise PCWP was coupled with signiﬁcant re-
ductions in RAP and PA pressure with stress, and an
acute decrease in the slope of the PA pressure-ﬂow
relationship, indicating an improvement in right
ventricular afterload (22). Given the enhanced after-
load sensitivity of the right ventricle in HFpEF, this
decrease in PA pressure would be expected to greatly
improve right ventricular performance as well (24).
Although decreases in rest and exercise PA pres-
sure were observed, there was no signiﬁcant effect of
nitrite on PVR or PA compliance at rest or during
exercise. Several animal studies have observed im-
provements in PA pressure and vascular remodeling
with nitrate or nitrite, but most of these model sys-
tems are characterized by more severe pulmonary
vascular disease (31). Subjects in the current study
displayed pulmonary vasoconstriction comparedwith normal reference values (32), but increases in
PVR and decreases in PA compliance were relatively
modest and not in the range associated with adverse
outcomes in heart failure patients (33). Mean PA
pressure-ﬂow slopes were extremely increased in the
study subjects, but this was predominantly due to
post-capillary (pulmonary venous) disease. Mean PA
pressure is equal to the product of CO and PVR sum-
med with downstream PCWP. In patients with
advanced pulmonary vascular disease, PA pressure is
high because of increased PVR, but in the current
study, increased PA pressure-ﬂow slopes were caused
almost exclusively by high PCWP. The current data
may not be applicable to patients with pulmonary
hypertension.
Other groups have noted improvements in the O2
cost of exercise with inorganic nitrite (34,35) in
contrast to the current study in which VO2 during
submaximal exercise was slightly enhanced. The
reason for the discrepancy is not clear, but may relate
to the level of work performed and the subjects
studied. For example, Larsen et al. (35) studied young
CENTRAL ILLUSTRATION Nitrite Improves Exercise Hemodynamics in
HFpEF: Mechanism of Hemodynamic Beneﬁt During Exercise From
Nitrite in Heart Failure
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Nitrite (NO2) is reduced to nitric oxide (NO) modestly under normoxic conditions, as at rest,
but markedly under conditions of venous hypoxia, as with exercise. This preferentially targets
hemodynamic derangements that develop during exercise in heart failure with preserved
ejection fraction (HFpEF), favorably reducing left ventricular (LV) ﬁlling pressures, enhancing
cardiac output reserve, and reducing pulmonary artery (PA) pressure during exercise, to
ultimately improve exercise capacity and reduce symptoms of exercise intolerance.
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1680healthy, well-trained men who were exercising at
4-fold higher VO2 (3 l/min) than in the current study’s
elderly, predominantly female HFpEF population
(0.7 l/min). The current results showing an increase in
VO2 with nitrite during submaximal exercise in
HFpEF agree with maximal exercise data from
Zamani et al. (30). We speculate that greater increases
in CO reserve from nitrite, possibly coupled with
nitrite-mediated improvements in skeletal muscle
microperfusion (36), are associated with less anaer-
obic glycolysis in exercising muscles in HFpEF pa-
tients and that this effect outweighs any ostensible
lowering of the O2 cost of exercise. This question
merits further study.
Plasma nitrite levels were assessed in a minority of
subjects, including 4 randomized to nitrite and 2 to
placebo. Levels were below assay at rest in all sub-
jects and after study drug infusion in those receiving
placebo. This is consistent with the low level of
plasma nitrite levels in humans under normal cir-
cumstances (0.05 to 0.3 mM) (19). In subjects receiving
active drug, a marked increase in plasma nitrite to
>8 mM developed, approximately 2-fold higher than
what has been observed with oral formulations (37).Although the low number of subjects with nitrite
levels measured limits our ability to examine
pharmacokinetics, it is notable that the observed
elimination half-life during 5 min of exercise was
10-fold faster than what has been reported in resting
humans (20). This is consistent with greater-than-
normal consumption of nitrite during exercise in the
study participants, presumably via greater reduction
to NO with stress.
CLINICAL IMPLICATIONS. Inorganic nitrate-nitrite
could be applied therapeutically through naturally
occurring sources such as beetroot juice or using oral
supplements, although these routes would not ach-
ieve plasma nitrite levels in the range of those
observed in the current study. Nitrite can also be
administered orally and via an inhaled, nebulized
device. Either of these routes may be suitable for
chronic administration in people with HFpEF.
Because of the rapid onset of action, the nebulized
preparation may prove useful as a rescue inhaler or
taken prophylactically before planned physical ac-
tivity to reduce symptoms of exercise intolerance.
The acute effects of inhaled nitrite on hemodynamics
are currently being tested in HFpEF (NCT02262078),
and larger phase II studies in this cohort are in the
planning stages.
Organic nitrates such as isosorbide mononitrate
also can enhance NO-cGMP and are commonly used in
managing people with HFpEF (38). However, organic
nitrates are limited by the development of tolerance,
increases in oxidative stress, and the development of
endothelial dysfunction (14). Organic nitrate toler-
ance can be reduced by ensuring an adequate nitrate-
free window, but renal sodium retention may offset
the beneﬁcial effects of long-term venodilation. In
contrast, there is no tolerance with inorganic nitrite,
and, because conversion of nitrite to NO occurs pre-
ferentially during exercise, there may be less sodium
retention and less risk of excessive BP reduction at
rest, which can be problematic in those with HFpEF
(15). The effect of organic nitrates on activity toler-
ance and exercise capacity is currently being inves-
tigated in the NEAT-HFpEF (Nitrate’s Effect on
Activity Tolerance in Heart Failure With Preserved
Ejection Fraction) trial (38).
STUDY LIMITATIONS. This study examined hemody-
namics and LV performance at rest and with low-level
exercise but not at peak exercise. This was done pri-
marily for feasibility, as it would be difﬁcult for sub-
jects to complete 2 maximal-effort exercise tests in a
timely fashion. Thus, we cannot determine whether
beneﬁts observed during low-level exercise would
extend to peak exercise, although the greater venous
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Sodium nitrite, a
source of NO, improves hemodynamics during exercise in pa-
tients who have HFpEF, supporting a pathophysiological role for
abnormal NO signaling in this condition.
TRANSLATIONAL OUTLOOK: Randomized trials of nitrite
therapy are needed to evaluate longer term effects on functional
capacity and clinical outcomes in patients with HFpEF.
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1681hypoxia and acidosis at peak would only be expected
to further potentiate the beneﬁt. Furthermore, this
level of activity is clinically meaningful in that it re-
ﬂects the level of physical work performed in activities
of daily life in typical older people with HFpEF. Right
ventricular function and right ventricle–PA coupling
may be improved by nitrite, but they were not
assessed in this study.
CONCLUSIONS
Inorganic nitrite favorably attenuates hemodynamic
derangements that develop during exercise in
individuals with HFpEF, including increased cardiac
ﬁlling pressures, exercise-induced pulmonary hyper-
tension, and inadequate CO reserve. Beneﬁcial effects
of nitrite are mediated by both vascular unloading and
direct myocardial effects, which are more pronounced
during exercise compared with steady state. Prospec-
tive trials testing chronic nitrite therapy in patients
with HFpEF are warranted.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Barry A. Borlaug, Division of Cardiovascular Diseases,
Department of Medicine, Mayo Clinic Rochester,
Mayo Clinic and Foundation, 200 First Street SW,
Rochester, Minnesota 55905. E-mail: borlaug.barry@
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